Philippines Oral Anti-Diabetic Drug Market Size (2024 - 2029)

Philippines Oral Anti-Diabetic Drug Market Analysis

The Philippines Oral Anti-Diabetic Drug Market size is estimated at USD 202.20 million in 2024, and is expected to reach USD 251.32 million by 2029, growing at a CAGR of greater than 4% during the forecast period (2024-2029).

A new disease known as a SARS-CoV-2 viral strain brings on COVID-19. Most infected individuals will experience mild to moderate respiratory disease and recover without special care. Serious illnesses are more likely to affect the elderly and people with underlying medical disorders such as diabetes, hypertension, heart disease, lung disease, obesity, and cancer. The virus enters the heart, lungs, and other bodily cells, triggering inflammatory changes that harm several organs and cause inflammation. 

Systemic inflammation and diabetes have been linked. Studies have shown that individuals with diabetes had increased viral entry, a lowered immune response, reduced viral clearance, and dysregulated inflammatory markers. Diabetes patients may be just as susceptible to COVID-19 infection as healthy individuals.

On the other hand, because diabetes is a core component of the illness, people with diabetes have a greater risk of hospitalization, ICU admissions, severe sequelae, and fatality after contracting COVID-19. Diabetes patients may have an equal chance of contracting COVID-19 as people without the disease. However, because diabetes is a key illness feature, those who get COVID-19 are more likely than those without diabetes to require hospitalization, be admitted to an intensive care unit (ICU), experience severe consequences, and die.

The insulin medication category holds a substantial market share. Insulin is used by more than 100 million individuals globally, including 100% of those with Type 1 diabetes and 10% to 25% of those with Type 2 diabetes. Only a few insulin producers are operating on the market, and insulin production is complex. As a result, there is intense competition among these companies, which always work to meet patients' needs by offering insulin of the best caliber.

High blood sugar levels caused by poor insulin generation and activity characterize the complex disease known as diabetes. The pancreatic hormone insulin regulates the body's blood sugar levels. Uncontrolled diabetes has several negative effects, such as renal failure, blindness, leg amputation, heart attack, and stroke. Data from the DOST-FNRI indicate that 14.2% of people have prediabetes. Out of every five Filipinos, one develops diabetes or prediabetes, which together causes abnormal glucose levels.

Philippines Oral Anti-Diabetic Drug Industry Segmentation

Orally administered antihyperglycemic drugs reduce blood glucose levels. They are often used in type 2 diabetes care. The Philippines oral anti-diabetic drug market is segmented into drugs. The report offers the market size in value terms in USD and Volume in terms of Unit for all the abovementioned segments.